Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698754 | 0.85 | MAPK1 (0.50) | NNMTHCAR3HCAR2 | |
| SCHEMBL29364292 | 0.84 | HCAR3 (0.46) | NNMTHCAR3HCAR2 | |
| SCHEMBL6700450 | 0.84 | HCAR3 (0.46) | NNMTHCAR3HCAR2 | |
| SCHEMBL6696009 | 0.82 | HCAR3 (0.42) | NNMTHCAR3HCAR2 | |
| SCHEMBL11546416 | 0.81 | HCAR3 (0.73) | NNMTEPHX2HCAR3HCAR2SMN1; SMN2 | |
| SCHEMBL2564435 | 0.80 | NNMT (0.50) | NNMTEPHX2HCAR3 | |
| SCHEMBL14185002 | 0.78 | NNMT (0.67) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL2746892 | 0.77 | NNMT (0.61) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL5205802 | 0.76 | NNMT (0.60) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL3132342 | 0.76 | NNMT (0.59) | NNMTEPHX2HCAR3HCAR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | NNMT 2846/4885EPHX2 2259/4885HCAR3 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.